Cooperative Agreement 70NANB20H143

This Cooperative Agreement award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $1,000,000 in funding to the Virginia Biotechnology Research Park Corporation (dba Activation Capital) to develop a robust pharmaceutical cluster program called the Alliance for Building Better Medicine in the Richmond/Petersburg region of Virginia. Over an 18-month period, the awardee will work with 23 core partners, including three direct...

This Project Grant award from the National Science Foundation (NSF) under its Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $275,000 to Tectaria Bio LLC to engineer cell lines with activated proteasomes for increased biomanufacturing efficiency. The project aims to test the feasibility and application of a novel technology to significantly increase the protein production capabilities of cell lines used in the manufacture of biologics, gene therapies, and vaccines....

This $294,947 Project Grant awarded by the National Science Foundation (NSF) under its Technology, Innovation, and Partnerships (CFDA 47.084) program will fund the development of a software tool to automate the creation of drug repurposing development plans. The tool aims to address the challenges and inefficiencies in the current manual process of generating these regulatory plans, which is often time-consuming and error-prone. The proposed solution leverages advances in natural language...

This award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $303,864 to Core Biotherapeutics Inc., a for-profit organization, to develop a platform for designing disruptive drug candidates that can address high unmet medical needs. The project aims to determine the biological laws governing molecular networks that drive diseases and program these into an efficient, scalable algorithm for drug target discovery. This...

This Project Grant award from the National Institute of Child Health and Human Development (NICHD) under CFDA Program 93.865 (Child Health and Human Development Extramural Research) aims to establish proof-of-concept for applying targeted fluorination to enhance the pharmacological properties of recombinant protein therapeutics (RPTs) for the treatment of inborn errors of metabolism. The $306,873 award to Halide Biologics, Inc. will fund research to improve the stability and cost-efficiency of...

This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training Program (CFDA 93.859), provides $275,765 to Opera Bioscience, Inc. to develop a platform for cost-effective production of recombinant proteins and growth factors for therapeutic applications. The project aims to adapt Opera Bioscience's proprietary bacterial protein secretion technology to create an optimized, safe production strain and define an optimal...

This $306,656 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development of a novel biotechnological approach to synthesize heparin-like anticoagulant drugs using engineered microbial cellular factories. The funded project, led by awardee Bioparin, LLC, aims to expeditiously produce unfractionated heparin (UFH) and low molecular weight heparins (LMWHs) as alternatives to the current...

This federal Project Grant award of $150,000 from the Food and Drug Administration (FDA) under the FDA Research program (CFDA 93.103) will support the Critical Path Institute's (C-Path) 4-day "C-Path Global Impact Conference." The purpose of this conference is to showcase the work of C-Path's public-private partnerships (PPPs) in generating solutions to accelerate drug development, with a focus on novel therapeutics for challenging conditions in neurology, rare/orphan diseases, and...

This $350,000 Project Grant award from the National Center for Advancing Translational Sciences (NCATS), under the 93.350 CFDA program, supports the development of the Codomax EPI-MAX platform. This integrated omics and computational technology leverages cellular stress responses to enhance the production of difficult-to-express therapeutic proteins, with a focus on improving secretion and preventing aggregation in the Pichia pastoris expression system. The key products or services to be...

This SBIR Phase II Project Grant awarded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) provides $1,219,222 to Nirrin Technologies Inc. to continue development of their tunable laser spectrometry system for rapid analysis of biopharmaceutical formulations. The goal is to optimize the design, fabricate 6 beta systems, and prepare them for external validation testing with major biopharmaceutical companies....